Rhabdomyolysis induced by simvastatin-diltiazem interaction in unrecognized hypothyriodism
- Author:
- No author available
- Journal Title:
- JOURNAL OF GERIATRIC CARDIOLOGY
- Issue:
- 2
- DOI:
- No doi available
- Key Word:
- Simvastatin;diltiazem;drug-interaction;rhabdomyolysis;hypothyriedism
Abstract： Simvastatin,a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,is widely prescribed to patients with hypercholesteremia and its muscular toxicity has been widely reported.The metabolism of simvastatin depends on the enzymic activity of cytochrome P450 3A4 (CYP3A4) and inhibitors of CYP3A4 can result in clinical events by interacting with simvastatin.Diltiazem is a moderate inhibitor of CYP3A4,which is known to increase the serum concentration of simvastatin.Here we report a patient with unrecognized hypothyroidism who had been stable for more than one year on low-dose simvastatin therapy of hypercholesteremia and rhabdomyolysis occurred with the addition of diltiazem.This is one of scanty reports of rhabdomyolysis induced by simvastatindiltiazem drug interaction,especially in hypothyroid patient.This case reminds the clinicians that although diltiazem as a moderate CYP3A4 inhibitor can be used cautiously with small doses of CYP3A4-dependent statius (eg,simvastatin),these two commonly used drugs should be avoided in hypothyroid patient.
- [1]Hall SD,Sunblad KJ,Mousa O,etc.The interaction of diltiazem with simvastatin.[J].2000,67(3).
- [2]JACEK OWCZAREK,MAGDALENA JASINSKA,DARIA ORSZULAK-MICHALAK.The Influence of Simvastatin at High Dose and Diltiazem on Myocardium in Rabbits, the Biochemical Study[J].2006,63(5).
- [3]Brown WV.Safety of statins.[J].2008,19(6).
- [4]Faiza A, Qari.Severe rhabdomyolysis and acute renal failure secondary to use of simvastatin in undiagnosed hypothyroidism.[J].2009,20(1).
- [5]A L, Masica,N E, Azie,D C, Brater,etc.Intravenous diltiazem and CYP3A-mediated metabolism.[J].2000,50(3).
- [6]Krum H,Martin J.Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class: Are They Clinically Relevant?[J].2003,26(1).
- [7]Vladutiu GD.Genetic predisposition to statin myopathy.[J].2008,20(6).
- [8]Martin JE,Cavanaugh TM,Trumbull L,etc.Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.[J].2008,22(1).
- [9]csu.buffalo.edu,Marinides G,Sauret JM,etc.Rhabdomyolysis.[J].2002,65(5).
- [10]Magee CC,Bae J,Jarcho JA,etc.Statin specific toxicity in organ transplant recipients: Case report and review of the literature[J].2002,15(3).
- [11]Yeo WW,Ramsay LE,Yeo KR,etc.Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients.[J].1999,48(4).
- [12]N, Kanathur,M G, Mathai,R P, Byrd,etc.Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis.[J].2001,94(9).
- [13]Niemi M,Neuvonen PJ,Backman JT.Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.[J].2006,80(6).
- [14]Braathen P,Skovlund E,Molden E.Risk Management of Simvastatin or Atorvastatin Interactions with CYP3A4 Inhibitors.[J].2008,31(7).
- [15]Fogo AB,Franklin DB,Najafian B.Acute renal failure and myalgia in a transplant patient.[J].2007,18(11).
- [16]Stephen I, Rifkin.Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report.[J].2008,10(11).